Investor sues Sanofi over drug rejection

What's a drug maker to do? Get a new product to market, and you might get sued by patients over side effects. See a product fail the approval test, and it's investors who hit the streets with torches and pitchforks.

Witness Sanofi-Aventis, which just got slapped with a purported class-action lawsuit on behalf of an institutional investor. The product in question: Acomplia, a weight-loss drug rejected by the FDA in June. The investor alleges Sanofi hid data that showed Acomplia could cause depression. Thus stock-buyers were misled into thinking the drug could be a blockbuster, netting millions for the company and, in turn, boosting share price. Instead, Sanofi expects a four-year delay before gaining FDA approval.

Meanwhile, Acomplia is approved for obesity in the EU, and regulators there will allow some positive data from a type 2 diabetes trial to go onto its label now. Sanofi says it plans to ask regulators in 2009 to approve the drug for type 2 diabetes.

- check out this release on the lawsuit
- read the lawsuit article from CNN Money
- see this Acomplia news from the EU in Forbes

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.